| Ticker: NMED | 308 12th Avenue South | |
| Exchange: NASDAQ-Small Cap Market | Buffalo, Minnesota 55313 | |
| Industry: Wholesale | (612) 682-9288 |
| Type of Shares: | Common Shares | Filing Date: | 8/12/96 | |
| U.S. Shares: | 1,250,000 | Offer Date: | 9/26/96 | |
| Non-U.S. Shares: | 0 | Filing Price: | $3.50 | |
| Primary Shares: | 1,250,000 | Offer Price: | $3.50 | |
| Secondary Shares: | 0 | Gross Spread: | $0.35 | |
| Offering Amount: | $4,375,000 | Selling: | $0.17 | |
| Expenses: | $275,000 | Reallowance: | ||
| Shares Out After: | 4,405,524 |
| Manager | Tier | Phone |
| Miller, Johnson & Kuehn Incorporated | Lead Manager | (612) 544-6660 |
| Auditor: Ernst & Young | |||||
| Audited Income | Latest Unaudited Income | Prior Unaudited Income | Balance Sheet | ||
| 12/31/95 | 6/30/96 | 6/30/95 | 6/30/96 | ||
| Revenue: | $0.84 | $1.09 | $0.28 | Assets: | $1.48 |
| Net Income: | -$0.96 | -$0.25 | -$0.41 | Liabilities: | $0.52 |
| EPS: | -$0.30 | -$0.06 | -$0.16 | Equity: | $0.97 |
Note: Dollar amounts are in U.S. millions; Audited figures expressed as full year, unaudited figures are partial year | |||||
| Business Description |
| The company develops and sells generic critical care nutrition products for the hospital/nursing home market, as well as private label nutrition products for sale through regional and national retail chains. The company's products are manufactured using ingredients, formulas and processes comparable to those of national brand products. The company currently has six critical care nutrition products and three private label nutrition products. The company intends to expand its existing product lines and is also currently in the early stages of developing an infant formula, which is not expected to be available for sale for at least one year. The company's strategy has been to focus on the development and sale of a line of generic critical care nutrition products for patients who are being treated in intensive care units. Certain of these products contain unique ingredients or proportions of ingredients to meet the metabolic requirements of specific patient populations. The company markets its critical care nutrition products to hospitals and other health care providers as a less expensive, generic alternative to the established products offered by major manufacturers. |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for development of additional products, marketing and working capital. |
©1996 IPO Data Systems, Inc. - All rights reserved.